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Summary
Holoprosencephaly (HPE), a common defect of human
forebrain development, is associated with haploinsuf-
ficiency for genes encoding Sonic Hedgehog (SHH)
pathway components. Clinical expression of HPE
is extremely variable, but it is rarely associated with
defects in other SHH-dependent structures, such as
limbs. Here we report that mice lacking the transmem-
brane protein Cdo, previously implicated in myogene-
sis, display HPE with strain-specific severity and with-
out limbdefects,modelinghumanHPEand implicating
modifier genes as a cause of variability. Shh target
gene expression is reduced in the developing fore-
brains of Cdo2/2 mice, and Cdo positively regulates
Shh signaling in vitro. Our data suggest that Cdo
enhances pathway activity in multiple ways, includ-
ing at signal reception and via a parallel mecha-
nism required at the level of Gli transcription factors.
Specific Cdo domains required for its promyo-
genic effect are dispensable for its Shh signaling
role, suggesting that Cdo has multiple, independent
functions.
Introduction
Holoprosencephaly (HPE) is the most common struc-
tural anomaly of human brain development, with a prev-
alence of w1 in 250 conceptuses and w1 in 16,000
at birth (Muenke and Beachy, 2001; Yamada et al.,
2004). The most severe form (alobar HPE) is character-
ized by a complete failure to form an interhemispheric
fissure in the prosencephalon, resulting in a single brain
ventricle. Progressively less severe forms (semilobar
and lobar HPE, respectively) are characterized by
graded degrees of forebrain cleavage, but the range
of midline defects extends from most to least severe
in an uninterrupted continuum referred to as the HPE
spectrum (Ming and Muenke, 2002; Muenke and
Beachy, 2001). Associated craniofacial anomalies ex-
tend from cyclopia with overlying proboscis through
HPE ‘‘microsigns’’ such as solitary median maxillary
central incisor. Mutations in eight different genes have
been identified in human HPE, but these account for
only w20% of the total cases examined (Ming and
Muenke, 2002). Prominent among HPE genes are sev-
eral that encode components of the Sonic Hedgehog
(SHH) pathway, including SHH itself, PTCH1, and GLI2
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2003). Strikingly, phenotypic heterogeneity is observed
even in familial forms of HPE, in which it is estimated
that among obligate mutation carriers, 37% will have
HPE, 27% will display microsigns of HPE, and 36% will
have no clinical manifestation (Cohen, 1989; Ming and
Muenke, 2002). Potential explanations for this variability
include (1) genetic influences, such as haploinsuffi-
ciency for a second HPE gene or other more common
genetic polymorphisms, and (2) environmental insults
at specific times during fetal development (Cohen and
Shiota, 2002; Cordero et al., 2004; Ming and Muenke,
2002; Nanni et al., 1999).
Hedgehog (Hh) family proteins activate an evolution-
arily conserved signal transduction pathway (Lum and
Beachy, 2004). The transmembrane protein Patched1
(Ptch1) functions to inhibit the activity of a second trans-
membrane protein, Smoothened (Smo); binding of Hh
proteins to Ptch1 relieves this inhibition, stimulating
a signaling pathway that culminates in induction of tar-
get genes via the Ci/Gli family of transcription factors.
Shh signaling regulates growth, patterning, and mor-
phogenesis of a wide variety of body structures, includ-
ing the limbs, axial skeleton, central nervous system,
face, and others (McMahon et al., 2003). Mice lacking
Shh display profound defects in development of these
structures and have severe HPE (Chiang et al., 1996).
A conundrum of human HPE is that, even in severely
affected patients, including those with mutations in
SHH pathway genes, the limbs and internal organs are
rarely affected (Muenke and Beachy, 2001). While sev-
eral mouse models of HPE exist (Cohen and Shiota,
2002), none display both the unexplained features of hu-
man HPE described above, i.e, the wide spectrum of
phenotypes and the lack of involvement of other
Shh-dependent structures.
Cdo (also known as Cdon) is a member of the Ig super-
family that positively regulates skeletal muscle develop-
ment as a component of cell surface complexes that
contain several transmembrane receptors and cell-cell
adhesion molecules, including the closely related pro-
tein, Boc; the Ig superfamily receptor, neogenin, and
its ligand, netrin-3; and N- and M-cadherin (Cole et al.,
2004; Kang et al., 1998, 2002, 2003, 2004). Unexpect-
edly, mice lacking Cdo on a mixed genetic background
display facial defects associated with microforms of
HPE (Cole and Krauss, 2003). We report here that
Cdo2/2 mice on a C57Bl/6 background display a severe
form of HPE but without defects in limb development,
thus mimicking human HPE and implicating modifier
genes as a likely cause of the variable penetrance
and expressivity of this malady. Additionally, Cdo2/2
mice have reduced Shh target gene expression, and
Cdo positively regulates Shh signaling in vitro, linking
Cdo to the most frequently disrupted pathway in human
HPE. Finally, the structural requirements for Cdo’s
ability to regulate Shh signaling activity are distinct
from those required for its role in promoting myogene-




Severe HPE and Reduced Shh Target Gene
Expression in C57BL/6 Cdo2/2 Mice
Mice homozygous for a targeted mutation of Cdo on
a mixed 129/Sv 3 C57BL/6 background display cranio-
facial microsigns of HPE with w95% penetrance; this
is associated with w35% perinatal lethality (Cole and
Krauss, 2003). On a 129/Sv background, mice lacking
Cdo also showed microsigns of HPE, but the penetrance
was reduced tow50% and no perinatal lethality was ob-
served (unpublished data). Congenic Cdo+/2 C57BL/6
mice were derived by backcrossing; intercrosses of
such animals revealed >80% perinatal lethality among
Cdo2/2 offspring, which had severe forms of HPE. Anal-
ysis of newborn mice and embryos typically revealed
cebocephalic faces (characterized by a single centrally
located nostril, ocular hypotelorism [close-set eyes],
and midface hypoplasia) (Figures 1B and 1C–1E), in-
complete cleavage of the forebrain resulting in a single
ventricle (Figures 1D–1J), and absence of, or rudimen-
tary, olfactory bulbs (Figure 1H). Interestingly, develop-
mental patterning of the limbs and axial skeleton was
normal in these animals (Figures 1A, 1C, and data not
shown), similar to human HPE where such anomalies
are rare (Muenke and Beachy, 2001).
The prechordal plate (PCP) mesendoderm functions
as a source of signals, including Shh, required for induc-
tion of ventral forebrain structures and subsequent
patterning of the midline of the forebrain and midface;
experimental removal of the PCP from vertebrate em-
bryos results in severe HPE (for review, see Muenke
and Beachy, 2001; Rubenstein and Beachy, 1998). Shh
produced by the PCP induces expression of genes, in-
cluding Shh itself, in the developing ventral forebrain
(Cordero et al., 2004; Rubenstein and Beachy, 1998).
Cdo expression is repressed by Shh signaling and is
therefore dorsally restricted in the developing CNS, in-
cluding the forebrain (Mulieri et al., 2000; Tenzen et al.,
2006 [in this issue of Developmental Cell]). However,
Cdo is expressed transiently in ventral mesodermal
structures that produce Shh (Tenzen et al., 2006), includ-
ing the PCP at E8.5 (Figure 2A).
If the reason Cdo2/2 embryos display HPE is that Cdo
functions in the PCP to modulate Shh expression or
signaling, it would be predicted that expression of Shh
and/or pathway target genes would be reduced in the
developing ventral forebrain. mRNA in situ hybridization
analysis indicated that Shh expression at E8.75 was
similar in the PCP and notochord of Cdo+/+ and Cdo2/2
embryos, but was reduced in the developing ventral
forebrain at this stage and at E9.5 (Figures 2B and 2C).
Although we cannot exclude subtle differences in the
timing or extent of Shh expression in the PCP of Cdo2/2
embryos, these data suggest that loss of Cdo may result
in disruption of Shh signaling in or from the PCP, with
a consequent reduction of Shh expression at secondary
sites. Consistent with this model, expression of the
direct Shh target genes,Gli1 andPtch1, and the Shh-de-
pendent ventral forebrain marker, Nkx2.1 (Pabst et al.,
2000), was reduced in the developing ventral forebrain
of Cdo2/2 embryos, relative to controls (Figures 2D–
2F). Additionally, expression of Fgf8 in the prosenceph-
alon, maintenance of which is dependent on Shh signal-ing (Ohkubo et al., 2002), was reduced in E9.0 Cdo2/2
embryos, whereas it was unaffected at the midbrain-
hindbrain boundary (Figure 2G). These results suggest
that Cdo functions to regulate Shh signaling specifically
during patterning of the ventral anterior midline and pro-
vide an explanation for the HPE seen in Cdo2/2 mice.
Cdo Positively Regulates Shh Signaling In Vitro
Studies in culturedDrosophila cells suggested that a pu-
tative fruit flyCdo ortholog is involved in Hh signal trans-
duction (Lum et al., 2003). To assess whether Cdo might
function to regulate Shh signaling, mammalian cell cul-
ture assays with a Gli-dependent luciferase reporter
were performed. 10T1/2 mouse embryo fibroblasts
were transiently transfected with the reporter construct
and treated with a soluble, active form of Shh, ShhN.
ShhN strongly stimulated luciferase activity, and the
response was completely blocked by the Smo inhibitor,
cyclopamine (Figure 3A). Cotransfection of an expression
vector containing a rat Cdo cDNA enhanced ShhN-
dependent reporter activity 2.0- to 2.5-fold in a fully
Figure 1. C57BL/6 Mice Lacking Cdo Have HPE
(A and B) Newborn Cdo2/2 mouse (A) displays a cebocephalic face
with a single nostril (arrow, [B]).
(C–E) Whole Cdo+/+ and Cdo2/2 embryos at E15.5 (C) and E12.5 (D
and E). Arrows: midline defects include cebocephaly (C) and incom-
plete forebrain clefting (D and E).
(F and G) Hematoxylin and eosin-stained sections of E11.5 Cdo+/2
and Cdo2/2 embryos. Note the paired lateral ventricles in the
Cdo+/2 embryo (F) and single ventricle in the Cdo2/2 embryo (G).
Bar, 0.2 mm.
(H) Dissected brains of E18.5 Cdo+/2 and Cdo2/2 embryos. Arrows:
presence or absence of olfactory bulbs.
(I and J) Nissl-stained sections through brains shown in (H).
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659Figure 2. Decreased Shh Target Gene Expression in Developing Forebrains of Cdo2/2 Embryos
(A) Cdo reporter expression in E8.5 PCP (arrows). Left to right: dorsal, ventral, lateral views.
(B–D, F, and G) Whole-mount in situ hybridization. Shh at E8.75 (B) and E9.5 (C); Gli1 at E9.5 (D); Nkx2.1 at E9.5 (F); Fgf8 at E9.0 (G).
(E) Ptch1 reporter expression at E9.0.
Asterisks (B–G), ventral region of the optic vesicle (note decreased Shh target gene expression anterior to this structure, in developing ventral
forebrains of Cdo2/2 embryos); arrowheads (B), Shh expression in developing ventral forebrain; brackets (C–G), wild-type expression domain;
arrows (G), mid-hindbrain boundary. (B–G) Left two panels, lateral view; right two panels, ventral view, except (G), frontal view. Bars, 0.2 mm;
except (A), left two panels of (B), and right two panels of (F), 0.1 mm.
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(A, C, and E) Gli-luc reporter assays6 Shh with cotransfection of the indicated ratCdo (rCdo) and mouse Cdo (mCdo) RNAi expression plasmids
(+). 10T1/2 cells were transfected with control vectors (2) as described in Experimental Procedures. Data are reported as relative light units (RLU;
luciferase/Renilla internal control). Values are means 6 1 SD from at least three experiments, each performed in triplicate. Cyc, cyclopamine.
(B) Western blot analysis of endogenous Cdo protein levels in 10T1/2 cells plated at the indicated densities and harvested as pictured 24 hr later.
(D) Western blot analysis of RNAi-mediated knockdown of endogenous Cdo protein in 10T1/2 cells.
(F) TRE-luc reporter assays6 cotransfection with activated H-Ras vector,6mCdo RNAi vector. Transfections performed and values reported as
in (A), (C), and (E).
(G) RT-PCR analysis of endogenous Ptch1 and Gli1 mRNA expression in 10T1/2 cells transfected with the indicated rCdo and mCdo RNAi vec-
tors, 6 Shh treatment. Gapdh mRNA was used as a control.cyclopamine-sensitive manner, but had no effect in the
absence of ShhN (Figure 3A).
Efficient induction of Gli-dependent reporter activity
by Shh or constitutively active Smo requires high cell
density (Taipale et al., 2000). 10T1/2 cells express low
levels of Cdo endogenously (Cole et al., 2004; Kang
et al., 2004); interestingly, the amount of Cdo protein
produced by these cells increased proportionally with
increasing cell density (Figure 3B). To assess the role of
endogenous Cdo in regulating Shh signaling in 10T1/2
cells, an RNAi approach was pursued. Cotransfection
of a mouseCdoRNAi vector dose-dependently inhibitedShhN-mediated reporter activity, and transfectants
showed a significant reduction of endogenous Cdo pro-
tein relative to control cells (Figures 3C and 3D). Four
independent RNAi sequences targeted against Cdo
that reduced Cdo protein levels also inhibited reporter
activity, while one that did not reduce Cdo levels had
no effect on reporter activity (data not shown). Further-
more, cotransfection of the rat Cdo expression vector,
which is not fully conserved at the sequence used to
knockdown endogenous mouse Cdo and is impervious
to the effects of the RNAi vector (data not shown),
rescued the ability of ShhN to activate the reporter
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661(Figure 3E). In contrast, RNAi to Cdo did not reduce the
ability of activated H-Ras to stimulate an AP-1 (TRE)-de-
pendent reporter (Figure 3F). Importantly, overexpres-
sion of Cdo enhanced, and RNAi to Cdo reduced, induc-
tion of the endogenousGli1andPtch1genes in response
to ShhN (Figure 3G). Similar results were seen with
NIH3T3 cells (Figure S1 in the Supplemental Data avail-
able with this article online). It is concluded that Cdo pos-
itively regulates Shh-initiated signaling to stimulate Gli-
dependent transcription and that Cdo may contribute
to the density dependence of pathway activity observed
in reporter assays in vitro.
One way Cdo enhances Shh signaling is through direct
binding to Shh, perhaps as an accessory receptor for
Ptch1 (Tenzen et al., 2006). To test this notion further,
we assessed the role of Cdo in activation of the pathway
by components downstream of Shh. Overexpression
of Cdo enhanced reporter activity induced by a constitu-
tively active mutant of Smo (SmoW539L; SmoA1)
(Taipale et al., 2000; Xie et al., 1998) or by Gli1 itself by
w2-fold (Figures 4A and 4B), similar to Cdo’s effect on
ShhN (Figure 3A). Furthermore, two independent Cdo
RNAi constructs inhibited SmoA1- and Gli1-dependent
reporter activity (Figures 4C and 4D, and Figure S1,
which shows that Cdo RNAi also reduced the response
of NIH3T3 cells to Gli1). RNAi-mediated knockdown of
Cdo did not alter Gli1 protein levels (Figure 4E).
These data suggest that, in addition to binding Shh,
Cdo provides a function at a downstream point of the
pathway, at the level of Gli transcription factors or regu-
lators of such factors. To explore this in more detail, we
analyzed additional Gli constructs. Gli2 is a primary
mediator of Shh signaling and contains a repression do-
main in its amino-terminal region and a bipartite activa-
tion domain in its carboxy-terminal region (Sasaki et al.,
1999). As seen with Gli1, RNAi to Cdo blocked Gli2-
mediated reporter activity without altering Gli2 protein
levels (Figures 4E and 4F). A Gli2 construct lacking the
amino-terminal repression domain (Gli2-DN2) has 4- to
5-fold higher activity than full-length Gli2 (Sasaki et al.
[1999] and Figure 4F) and its activity was also strongly
inhibited by Cdo RNAi (Figure 4F). The Gli2 carboxy-
terminal activation domain has been defined with
GAL4 DNA binding domain fusions and a reporter
controlled by the GAL4 binding site (Sasaki et al.,
1999). Chimeras containing the complete carboxy-
terminal region (designated BD-C) or two individually
active parts (BD-A1 and BD-A2) all showed similar activ-
ity on this reporter but, unlike full-length Gli2, were unaf-
fected by the coexpression of a Cdo RNAi construct
(Figure 4G). These results suggest that the need for
Cdo in Gli2-dependent reporter activity is explained nei-
ther by relief of its repression function nor stimulation
of its trans-activation function. We have not observed
obvious effects of Cdo overexpression or RNAi on the
subcellular localization of transfected Gli1 or Gli2 (data
not shown). Consistent with this, Gli1 containing the
nuclear localization sequence from SV40 large T antigen
(NF-Gli1), as well as this construct harboring the highly
active VP16 trans-activation domain in place of the
Gli1 trans-activation domain (NF-Gli1/VP16) (Kimura
et al., 2005), retained a significant level of sensitivity to
Cdo RNAi in activation of the Gli-dependent reporter
(Figure 4H).Regions of Cdo Required for Myogenesis
Are Dispensible for Shh Signaling
Cdo contains 5 Ig plus 3 fibronectin type III (FNIII) re-
peats in its ectodomain and a 270 amino acid cytoplas-
mic tail that does not resemble other proteins, and it
promotes myogenesis as a part of complexes with addi-
tional Ig receptors and cadherins (Kang et al., 2002,
2003, 2004). A ratCdo deletion mutant that lacks the first
FNIII repeat (DFN1) is selectively deficient in its ability to
bind cadherins and functions as a dominant-negative
factor in myogenesis assays (Kang et al., 2003). In con-
trast, the DFN1 mutant is as effective as full-length Cdo
in enhancing ShhN-dependent reporter activity and in
rescuing the effect of Cdo RNAi (Figures 4I and 4K).
Cdo’s cytoplasmic tail is also required for its promyo-
genic function (Kang et al., 1998), but a ratCdo construct
in which the intracellular region is replaced with GFP
(DICR1) was also effective at stimulating ShhN-depen-
dent transcription (Figures 4J and 4K). The structural
determinants of Cdo’s actions in myogenesis and Shh
signaling are therefore distinct, suggesting that Cdo
has multiple, independent functions.
Boc is the vertebrate protein most closely related to
Cdo, and they can bind directly to one another in a cis
fashion; although there may be some redundancy in their
function, studies in myoblasts suggest they can work to-
gether (Kang et al., 2002). To address whether Boc also
regulates Shh signaling, RNAi to Boc was tested for its
effects on the Gli-dependent reporter in 10T1/2 cells. As
seen for Cdo, cotransfection of a Boc RNAi expression
vector that effectively reduced Boc protein levels dimin-
ished reporter activity in response to ShhN or trans-
fected Gli1, though the degree of inhibition was some-
what less than that seen with Cdo RNAi (Figures 4L–4N).
A similar effect of Boc RNAi was seen with NIH3T3 cells
(Figure S1). Therefore, knockdown of either Cdo or Boc
reduced Shh pathway activity, and it is possible that
they may cooperate in regulation of Shh signaling.
Discussion
Mice that Lack Cdo: A Genetic Model of Human HPE
Cdo2/2mice of a 129/Sv background show facial micro-
forms of HPE with incomplete penetrance, while those
of a C57BL/6 background display semilobar HPE and
cebocephaly with >80% penetrance; limb development
is grossly normal in both strains. Cdo-deficient mice
therefore provide a genetic model of HPE that mimics
the major unexplained features of human HPE, i.e., the
wide phenotypic spectrum of forebrain and midface de-
fects, with minimal involvement of other Shh-dependent
structures. Furthermore, Cdo is intimately linked to the
Shh pathway, defects in which are the most frequent
known cause of human HPE (Ming and Muenke, 2002).
Together with the accompanying paper (Tenzen et al.,
2006), it is shown that Cdo functions to positively regu-
late Shh signaling in vivo and in vitro, likely by multiple
mechanisms.
Taken together, the results suggest that Cdo positively
regulates Shh signaling in and/or from the PCP in pat-
terning the midline of the ventral forebrain and midface.
The dependence of Shh signaling on Cdo in develop-
ment of these latter structures is intriguing, in that this
process is particularly sensitive to pathway signaling
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662Figure 4. Hh Pathway Analysis In Vitro and Effects of Cdo Deletion Mutants and Boc
(A–D) Gli-luc reporter assays with transfected SmoA1 (A and C) or Gli1 (B and D) expression vectors as activators and cotransfection of the in-
dicated rCdo and mCdo RNAi expression plasmids.
(E) Western blot analysis of transfected Gli1 and Gli2 levels in the absence and presence of increasing amounts of mCdo RNAi vector. Gli proteins
were detected by a Flag epitope tag, endogenous Cdo, and cadherin (used as a control) by antibodies to the native proteins.
(F and H) Gli-luc reporter assays with transfected Gli2 or Gli2-DN2 (F) and NF-Gli1 or NF-Gli1/VP16 (H) expression vectors as activators and
cotransfection of control or mCdo RNAi expression plasmids.
(G) GAL4-luc reporter assays with the control (GAL4-BD) and Gli2 activation domain-containing expression vectors (BD-C; BD-A1 and BD-A2) as
activators and cotransfection of control or mCdo RNAi expression plasmids.
(I and J) Gli-luc reporter assays 6 Shh with cotransfection of the indicated rCdo, mutant rCdo, and mCdo RNAi expression plasmids.
(K) Western blot analysis of expression of rCdo, DFNI, and DICR1 in transfected 10T1/2 cells.
(L and M) Gli-luc reporter assays 6 Shh (L) or transfected Gli expression vector (M) as activators with cotransfection of control or Boc RNAi
expression plasmids.
(N) Western blot analysis of RNAi-mediated knockdown of endogenous Boc protein in 10T1/2 cells.
(A–D, F–H, L, and M) Transfections were performed and values reported as in Figure 3.strength (Hu and Helms, 1999) and that coexpression of
Cdo and Shh is restricted to the PCP (and notochord).
Cdo may therefore function to regulate Shh signaling in
a region of the embryo in which very high pathway activ-
ity is needed and the consequent developmental out-
comes are dosage sensitive. Consistent with this possi-
bility, Cdo is not essential for Shh signaling in general,
even in C57BL/6 mice, as most Shh-dependent body
structures develop normally in Cdo2/2 animals. The lack
of a limb phenotype in holoprosencephalic Cdo2/2 mice
is noteworthy. Cdo is unable to regulate Shh signaling inthe posterior aspect of the developing limb because its
expression is restricted to more anterior regions via
high Shh activity itself in the posterior (Mulieri et al.,
2000; Tenzen et al., 2006). Additionally, a role for Cdo in
patterning the limb at the fringes of the Shh gradient
may be masked in Cdo2/2 animals by potential redun-
dancy with the closely related factor Boc, whose expres-
sion in the limb is virtually identical to that of Cdo; how-
ever, in contrast to Cdo, Boc is not expressed in the
PCP or notochord (Mulieri et al., 2002; Tenzen et al.,
2006). These observations provide a likely explanation
Cdo, Shh Signaling, and Holoprosencephaly
663of the selective Shh-like phenotype of Cdo2/2 mice and
a conceptual rationale for the similar phenotype of hu-
man HPE patients. It should be noted, however, that
RNAi to eitherCdo orBoc inhibited Shh signaling in vitro,
and additional work will be required to identify potentially
redundant versus cooperative functions of Cdo and Boc.
The modifier loci involved in the distinct phenotypic
consequences of loss of Cdo in the 129/Sv or C57BL/6
strains are not known, but the C57BL/6 background
also sensitizes mice lacking the BMP pathway regulator,
Tsg, to HPE (and other phenotypes) (Petryk et al., 2004).
It is highly likely that genetic variation analogous to that
found in different inbred strains of mice is widespread in
the human population and might be sufficient to account
for differences in penetrance and expressivity of HPE
phenotypes of individuals carrying predisposing muta-
tions, such as Shh haploinsufficiency. Severe HPE phe-
notypes could also be conferred on Cdo2/2 mice of the
less sensitive genetic background by removal of one
copy of Shh (Tenzen et al., 2006). Therefore, human
CDO could function as both a bona fide HPE gene and
a modifier of HPE genes.
Regulation of Shh Signaling by Cdo
RNAi toCdoblocks Shh signaling in cultured fibroblasts,
and it seems likely that Cdo enhances Hh pathway activ-
ity by multiple mechanisms, including (1) direct binding
of Shh ligand (Tenzen et al., 2006) and (2) signaling by
a parallel mechanism that regulates the Hh pathway at
the level of Gli transcription factors or regulators of Gli
factors. This second mechanism is consistent with the
observation that Cdo does not stimulate a Gli-depen-
dent reporter in the absence of ‘‘classical’’ pathway ac-
tivators (Shh itself, or transfected SmoA1, Gli1, or Gli2),
but is important for reporter activity induced by each. It
is possible that the need for Cdo at the level of Gli factors
is related to Cdo’s function as a coreceptor for other sig-
naling ligands, such as netrins (Kang et al., 2004). In this
regard, recent reports indicate that the Shh pathway
may require ‘‘basal’’ levels of activity of other signaling
pathways not directly stimulated by Shh signaling itself.
For example, the ERK and PI-3 kinase/Akt pathways are
required for several transcriptional and biological re-
sponses to Shh and Gli1 in vitro (Kessaris et al., 2004;
Riobo et al., 2006a, 2006b). Cdo may regulate signaling
via one or more of these pathways in fibroblasts to
gate Gli activity at a downstream point. The molecular
mechanism by which Cdo signaling modulates Gli activ-
ity is not clear, but studies with Gli1, Gli2, and mutants of
these factors indicate that it is not via alterations in pro-
tein stability, relief of a Gli transcriptional repression
domain, or stimulation of a Gli trans-activation domain.
Cdo may regulate Gli DNA binding activity or interaction
with an unidentified cofactor.
Cdo may therefore stimulate Shh signaling by more
than one mechanism, by binding to Shh at the cell sur-
face, perhaps as part of the Hh receptor complex, and
also by regulating parallel pathways that influence the
activity of Hh-responsive transcription factors. These
mechanisms are non-mutually exclusive. Again, how-
ever, neither of these Cdo functions is essential in vivo.
Cdo is not expressed in such Shh-dependent structures
as the most posterior aspect of the limb bud and the
ventral neural tube (floor plate being an exception), noris Boc. In these tissues, other Hh binding proteins may
substitute for the former function. For the latter function,
the required parallel pathway(s), if as generic as MAP
and PI-3 kinases, are likely to be activated in vivo in
more than one way. The strong dependence of cultured
fibroblast lines on Cdo may reflect their particular de-
pendence on this factor to provide such signaling func-
tion. It will be important in the future to identify the rela-
tive contributions in vivo of these distinct mechanisms
for both Cdo and Boc and whether there is any higher or-
der crossregulation that ties the mechanisms together.
Experimental Procedures
Mice
Cdo+/lacZ-1 and Cdo+/lacZ-2 mice of a mixed 129/Sv3 C57BL/6 back-
ground have been described (Cole and Krauss, 2003). The pheno-
types of mice homozygous for each mutation are similar except
that the CdolacZ-2 allele expresses lacZ in a pattern that mimics
endogenous Cdo expression, while the CdolacZ-1 allele expresses
lacZ extremely weakly. Each Cdo allele was placed directly onto
the 129/Sv background by crossing chimeric males produced by
injection of targeted ES cells into blastocysts with 129/Sv females.
To produce congenic Cdo+/2 C57BL/6 animals, males of the mixed
background were backcrossed with C57BL/6 females for ten gener-
ations. Genotyping was by PCR with Cdo allele-specific primers.
The two Cdo alleles were used interchangeably, except that
CdolacZ-2 mice were used to monitor Cdo expression in Figure 2A
and CdolacZ-1 mice were crossed with Ptch1+/tm1Mps mice (Goodrich
et al., 1997) so as to monitor Ptch1 lacZ reporter activity. Mice and
embryos were processed for RNA in situ hybridization, b-gal stain-
ing, and hematoxylin and eosin staining as previously described
(Cole and Krauss, 2003; Cole et al., 2004). More detailed information
on procedures with mice is available in the Supplemental Data.
Cells and Reporter Assays
10T1/2, NIH3T3, and 293T cells were cultured and transiently trans-
fected as described (Kang et al., 2004). ShhN (Roelink et al., 1995)
was produced by transfection of 293T cells and collection of condi-
tioned medium (CM) 6 days later. For initial reporter assays, a range
of CM dilutions were tested; Figure S2 shows thatCdoRNAi blocked
reporter activity over a 100-fold dilution range. For the reporter as-
says shown in Figures 3 and 4, the CM was diluted 100-fold with
DMEM plus 2% FBS; this dilution gave a maximal response (Fig-
ure S2). Reporter assays were generally performed as follows: cells
were inoculated on 6-well plates and 24 hr later transfected with a to-
tal of 1 mg DNA, including reporter and indicated expression vectors,
plus a Renilla luciferase vector as an internal control. The following
day, cells were passaged into 24-well plates at 50% confluence
and 24 hr later, where indicated, transferred to control or ShhN-con-
taining CM. Luciferase assays were performed 48 hr later; data are
reported as relative light units (luciferase activity/Renilla activity).
To assess RNAi-mediated knockdown, a GFP expression vector
was cotransfected with Cdo or Boc RNAi vectors, cells were sorted
for the presence of GFP, and GFP+ and GFP2 populations were an-
alyzed by Western blotting. For semiquantitative RT-PCR analysis
of endogenous Ptch1, Gli, and Gapdh, cells were transfected as
for assessment of RNAi efficacy and sorted for GFP expression; total
RNA was isolated from GFP+ cells and amplified as described (Gao
et al., 2005). More detailed information on the procedures described
in this section is available in the Supplemental Data.
Supplemental Data
Supplemental Data, including detailed experimental procedures and
two figures, are available online at http://www.developmentalcell.
com/cgi/content/full/10/5/657/DC1/.
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